Basic Information
RNALocate ID: | RLID:11002989 |
RNA Symbol: | hsa-miR-494-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-494 |
RNA ID: | miRBase:MIMAT0002816 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 20976003 |
Tissue/Cell Line: | Breast cancer cell line (MCF-7) |
Method: | Microarray |
Description: | Because of the suggested roles of extracellular miRNAs in signaling and diagnosis, we investigated whether the intracellular and extracellular miRNA composition are the same. To answer this question, we performed microRNA microarray analyses of MCF7 cellular (c) and extracellular (x) RNAs (Figure 2A), and found that about 66% of the released miRNAs are at an abundance that closely reflects the cellular miRNA abundance (Figures 2B and 2C). This finding is in agreement with a model wherein most, but not all miRNAs are released passively by mass action. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002330 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
RLID:01002331 | Cytosol | Cell line (HeLa) | 21695135 |
RLID:01002332 | Mitochondrion | HeLa cells | 27396686 |
RLID:01002333 | Mitochondrion | HeLa cells | 27563705 |
RLID:01002334 | Mitochondrion | Cell line (HeLa) | 21695135 |
RLID:01002335 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:01002336 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
RLID:11002990 | Exosome | Primary dendritic cells | 21505438 |
RLID:11002991 | Exosome | Brain tissue | 23382797 |
RLID:11002992 | Exosome | Plasma | 23663360 |
RLID:11002993 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11002994 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11002995 | Exosome | Serum | 24683445 |
RLID:11002996 | Microvesicle | Seminal plasma | 23539611 |
RLID:11002997 | Microvesicle | Follicular fluid | 23666971 |
RLID-D:11000483 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001248 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-494-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-54541 |
MNDR | hsa-miR-494-3p | Oral squamous cell carcinoma | MNDR-E-MI-54542 |
MNDR | hsa-miR-494-3p | Large cell neuroendocrine cancer | MNDR-E-MI-54543 |
MNDR | hsa-miR-494-3p | Medulloblastoma | MNDR-E-MI-54544 |
MNDR | hsa-miR-494-3p | B cell lymphoma of malt type | MNDR-E-MI-54545 |
MNDR | hsa-miR-494-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-54546 |
MNDR | hsa-miR-494-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-54547 |
MNDR | hsa-miR-494-3p | Lymphoma | MNDR-E-MI-54548 |
MNDR | hsa-miR-494-3p | Non-hodgkin lymphoma | MNDR-E-MI-54549 |
MNDR | hsa-miR-494-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-54550 |
MNDR | hsa-miR-494-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-54551 |
MNDR | hsa-miR-494-3p | Her2-receptor positive breast cancer | MNDR-E-MI-54552 |
MNDR | hsa-miR-494-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-54553 |
MNDR | hsa-miR-494-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-54554 |
MNDR | hsa-miR-494-3p | Prostate cancer | MNDR-E-MI-54555 |
MNDR | hsa-miR-494-3p | Gastric cancer | MNDR-E-MI-54556 |
MNDR | hsa-miR-494-3p | Alzheimer disease | MNDR-E-MI-54557 |
MNDR | hsa-miR-494-3p | Intracranial aneurysm | MNDR-E-MI-54558 |
MNDR | hsa-miR-494-3p | Bladder cancer | MNDR-E-MI-54559 |
MNDR | hsa-miR-494-3p | Brucellosis | MNDR-E-MI-54560 |
MNDR | hsa-miR-494-3p | Dysautonomia familial | MNDR-E-MI-54561 |
MNDR | hsa-miR-494-3p | Duchenne muscular dystrophy | MNDR-E-MI-54562 |
MNDR | hsa-miR-494-3p | Primary biliary cirrhosis | MNDR-E-MI-54563 |
MNDR | hsa-miR-494-3p | Leukemia | MNDR-E-MI-54564 |
MNDR | hsa-miR-494-3p | Cardiovascular disease | MNDR-E-MI-54565 |
MNDR | hsa-miR-494-3p | Lung cancer | MNDR-E-MI-54566 |
MNDR | hsa-miR-494-3p | Down syndrome | MNDR-E-MI-54567 |
MNDR | hsa-miR-494-3p | Parkinson disease | MNDR-E-MI-54568 |
MNDR | hsa-miR-494-3p | Breast cancer | MNDR-E-MI-54569 |
MNDR | hsa-miR-494-3p | Pancreatic cancer | MNDR-E-MI-54570 |
MNDR | hsa-miR-494-3p | Melanoma | MNDR-E-MI-54571 |
MNDR | hsa-miR-494-3p | Nephroblastoma | MNDR-E-MI-54572 |
MNDR | hsa-miR-494-3p | Colon cancer | MNDR-E-MI-54573 |
MNDR | hsa-miR-494-3p | Colon adenocarcinoma | MNDR-E-MI-54574 |
MNDR | hsa-miR-494-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-54575 |
MNDR | hsa-miR-494-3p | Ovarian cancer | MNDR-E-MI-54576 |
MNDR | hsa-miR-494-3p | Prostate adenocarcinoma | MNDR-E-MI-54577 |
MNDR | hsa-miR-494-3p | Carcinoma ductal breast | MNDR-E-MI-54578 |
MNDR | hsa-miR-494-3p | Glioblastoma | MNDR-E-MI-54579 |
MNDR | hsa-miR-494-3p | Glioma | MNDR-E-MI-54580 |
MNDR | hsa-miR-494-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-54581 |
MNDR | hsa-miR-494-3p | Temporal lobe epilepsy | MNDR-E-MI-54582 |
MNDR | hsa-miR-494-3p | Osteosarcoma | MNDR-E-MI-54583 |
MNDR | hsa-miR-494-3p | Liposarcoma | MNDR-E-MI-54584 |
MNDR | hsa-miR-494-3p | Liver cancer | MNDR-E-MI-54585 |
MNDR | hsa-miR-494-3p | Cervical squamous cell carcinoma | MNDR-E-MI-54586 |
MNDR | hsa-miR-494-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-54587 |
MNDR | hsa-miR-494-3p | Lung squamous cell carcinoma | MNDR-E-MI-54588 |
MNDR | hsa-miR-494-3p | Non-small cell lung cancer | MNDR-E-MI-54589 |
MNDR | hsa-miR-494-3p | Lung adenocarcinoma | MNDR-E-MI-54590 |
MNDR | hsa-miR-494-3p | Adrenocortical cancer | MNDR-E-MI-54591 |
MNDR | hsa-miR-494-3p | Ovarian carcinoma | MNDR-E-MI-54592 |
MNDR | hsa-miR-494-3p | Bladder urothelial carcinoma | MNDR-E-MI-54593 |
MNDR | hsa-miR-494-3p | Pancreatic adenocarcinoma | MNDR-E-MI-54594 |
MNDR | hsa-miR-494-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-54595 |
MNDR | hsa-miR-494-3p | Papillary renal cell carcinoma | MNDR-E-MI-54596 |
MNDR | hsa-miR-494-3p | Clear cell renal cell carcinoma | MNDR-E-MI-54597 |
MNDR | hsa-miR-494-3p | Biliary tract cancer | MNDR-E-MI-54598 |
MNDR | hsa-miR-494-3p | Cholangiocarcinoma | MNDR-E-MI-54599 |
MNDR | hsa-miR-494-3p | Esophageal cancer | MNDR-E-MI-54600 |
MNDR | hsa-miR-494-3p | Lung small cell carcinoma | MNDR-E-MI-54601 |
MNDR | hsa-miR-494-3p | Encephalopathy bovine spongiform | MNDR-E-MI-54602 |
MNDR | hsa-miR-494-3p | Synovial sarcoma | MNDR-E-MI-54603 |
MNDR | hsa-miR-494-3p | Stomach carcinoma | MNDR-E-MI-54604 |
MNDR | hsa-miR-494-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-54605 |
MNDR | hsa-miR-494-3p | Adenoma | MNDR-E-MI-54606 |
MNDR | hsa-miR-494-3p | Breast invasive carcinoma | MNDR-E-MI-54607 |
MNDR | hsa-miR-494-3p | Hepatocellular carcinoma | MNDR-E-MI-54608 |
MNDR | hsa-miR-494-3p | B-cell lymphoma | MNDR-E-MI-54609 |
MNDR | hsa-miR-494-3p | Retinoblastoma | MNDR-E-MI-54610 |
MNDR | hsa-miR-494-3p | Hodgkin lymphoma | MNDR-E-MI-54611 |
MNDR | hsa-miR-494-3p | Burkitt lymphoma | MNDR-E-MI-54612 |
MNDR | hsa-miR-494-3p | Mouth neoplasms | MNDR-E-MI-54613 |
MNDR | hsa-miR-494-3p | Gastrointestinal stromal tumor | MNDR-E-MI-54614 |
MNDR | hsa-miR-494-3p | Nasopharynx carcinoma | MNDR-E-MI-54615 |
MNDR | hsa-miR-494-3p | Multiple myeloma | MNDR-E-MI-54616 |
MNDR | hsa-miR-494-3p | Ovarian epithelial cancer | MNDR-E-MI-54617 |
MNDR | hsa-miR-494-3p | Nasopharyngeal cancer | MNDR-E-MI-54618 |
MNDR | hsa-miR-494-3p | Prostatic neoplasms | MNDR-E-MI-54619 |
MNDR | hsa-miR-494-3p | Pseudorabies | MNDR-E-MI-54620 |
MNDR | hsa-miR-494-3p | Pancreatitis chronic | MNDR-E-MI-54621 |
MNDR | hsa-miR-494-3p | Stroke lacunar | MNDR-E-MI-54622 |
MNDR | hsa-miR-494-3p | Tubulovillous adenoma | MNDR-E-MI-54623 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ARHGAP5 | Homo sapiens | RR00122451 |
TOP